13F value (AUM)
$11.1B
Avoro Capital Advisors
AVORO CAPITAL ADVISORS LLC
$11.1B
13F long value · 2026-Q2Positions26
CategoryAsset Manager
Quarters tracked9
● #486 of 581 by 13F value
Size rank 2/10
3 NEW4 ADD6 EXIT
Snapshot
Avoro Capital Advisors's 13F portfolio at a glance — size, concentration and this quarter's activity.
Positions
26 (4 unmapped)
Top 26 weight
99.8%
Quarters tracked
9
Latest 13F filed
Aug 14, 2026
New positions
3
Exits / near-exits
6
13F value by quarter
Total reported long value each quarter — fund flows plus market moves.
Top holdings — 2026-Q2
The fund's largest reported positions. The 26 shown cover 99.8% of the portfolio.
| Ticker | Issuer | Weight | Value | Shares | Since 2026-Q2 |
|---|---|---|---|---|---|
| UTHR | UNITED THERAPEUTICS CORP | 13.5% | $1.5B | 2.8M | +4.6% |
| — | ASCENDIS PHARMA | 12.2% | $1.4B | 5.1M | — |
| KRYS | KRYSTAL BIOTECH INC | 9.6% | $1.1B | 2.9M | -26.6% |
| MDGL | MADRIGAL PHARMACEUTICALS INC | 8.8% | $984.4M | 1.8M | -3.1% |
| ARGX | ARGENX SE | 8.3% | $927.8M | 1.0M | -15.5% |
| ARWR | ARROWHEAD PHARMACEUTICALS INC | 8.3% | $925.6M | 11.4M | — |
| KYMR | KYMERA THERAPEUTICS INC | 7.7% | $857.1M | 7.5M | -24.4% |
| RVMD | REVOLUTION MEDICINES INC | 3.9% | $430.2M | 2.3M | -29.7% |
| CYTK | CYTOKINETICS INC | 3.8% | $425.9M | 5.0M | -27.7% |
| CELC | CELCUITY INC | 3.2% | $355.7M | 3.4M | +20.1% |
| GPCR | STRUCTURE THERAPEUTICS INC | 3.2% | $351.8M | 6.6M | -15.5% |
| XENE | XENON PHARMACEUTICALS INC | 3.1% | $348.7M | 5.8M | -10.1% |
| DFTX | DEFINIUM THERAPEUTICS INC | 3.0% | $338.2M | 7.2M | -55.4% |
| — | UNIQURE NV | 2.8% | $309.9M | 6.7M | — |
| VERA | VERA THERAPEUTICS INC | 2.2% | $245.6M | 5.7M | -13.1% |
Quarterly changes — 2026-Q2
What Avoro Capital Advisors opened, added, trimmed and exited this quarter, largest dollar moves first.
| Action | Ticker | Issuer | Prev shares | Curr shares | Change | Value Δ |
|---|---|---|---|---|---|---|
| NEW | — | ASCENDIS PHARMA | — | 5.1M | — | +$1.4B |
| EXIT | ASND | ASCENDIS PHARMA | 5.1M | 0 | -100.0% | -$1.2B |
| EXIT | APLS | APELLIS PHARMACEUTICALS INC | 12.2M | 0 | -100.0% | -$491.7M |
| EXIT | CNTA | CENTESSA PHARMACEUTICALS PLC | 11.4M | 0 | -100.0% | -$454.0M |
| EXIT | TERN | TERNS PHARMACEUTICALS INC | 5.7M | 0 | -100.0% | -$300.2M |
| ADD | DFTX | DEFINIUM THERAPEUTICS INC | 5.0M | 7.2M | +43.8% | +$243.7M |
| ADD | CYTK | CYTOKINETICS INC | 3.3M | 5.0M | +50.0% | +$206.2M |
| EXIT | SLNO | SOLENO THERAPEUTICS INC | 2.3M | 0 | -100.0% | -$77.0M |
| NEW | COAG | HEMAB THERAPEUTICS HLDGS INC | — | 1.9M | — | +$70.7M |
| EXIT | — | ALKERMES PLC | 1.2M | 0 | -100.0% | -$42.4M |
Conviction over time
Portfolio weight of the current top long holdings, quarter by quarter — rising weight = growing conviction.